Sharanya Vidyadhar Paramshetti

Ms. Sharanya Vidyadhar Paramshetti

Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research. Mysuru, Mysore, India
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Life Sciences
Verified
Journal Article
Closed access
SPSharanya Vidyadhar Paramshetti
Sharanya Vidyadhar Paramshetti
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
STSIRAJUNISA TALATH
SIRAJUNISA TALATH
RORiyaz Ali M Osmani
Riyaz Ali M Osmani
ASAsha Spandana
Asha Spandana
ESEkta Singh
Ekta Singh

10 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SPSharanya Vidyadhar Paramshetti
Sharanya Vidyadhar Paramshetti
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
Adel Al FateaseAdel Al Fatease
Adel Al Fatease
SASultan Alshahrani
Sultan Alshahrani
UHUmme Hani
Umme Hani
RORiyaz Ali M Osmani
Riyaz Ali M Osmani
The first conductive polymers (CPs) were developed during the 1970s as a unique class of organic substances with properties that are electrically and optically comparable to those of inorganic semiconductors and metals while also exhibiting the desirable traits of conventional polymers. CPs have become a subject of intensive research due to their exceptional qualities, such as high mechanical and optical properties, tunable electrical characteristics, ease of synthesis and fabrication, and higher environmental stability than traditional inorganic materials. Although conducting polymers have several limitations in their pure state, coupling with other materials helps overcome these drawbacks. Owing to the fact that various types of tissues are responsive to stimuli and electrical fields has made these smart biomaterials attractive for a range of medical and biological applications. For various applications, including the delivery of drugs, biosensors, biomedical implants, and tissue engineering, electrical CPs and composites have attracted significant interest in both research and industry. These bimodalities can be programmed to respond to both internal and external stimuli. Additionally, these smart biomaterials have the ability to deliver drugs in various concentrations and at an extensive range. This review briefly discusses the commonly used CPs, composites, and their synthesis processes. Further highlights the importance of these materials in drug delivery along with their applicability in various delivery systems.

2 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
AMAsha Spandana K M
Asha Spandana K M
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
MRMohamed Rahamathulla
Mohamed Rahamathulla
KTKamal Yoonus Thajudeen
Kamal Yoonus Thajudeen
MAMohammed Muqtader Ahmed
Mohammed Muqtader Ahmed
JNJawahar Natarajan
Jawahar Natarajan
Bromocriptine (BCR) presents poor bioavailability when administered orally because of its low solubility and prolonged first-pass metabolism. This poses a significant challenge in its utilization as an effective treatment for managing Parkinson’s disease (PD). The utilization of lipid nanoparticles can be a promising approach to overcome the limitations of BCR bioavailability. The aim of the research work was to develop and evaluate bromocriptine-loaded solid lipid nanoparticles (BCR-SLN) and bromocriptine-loaded nanostructured lipid carriers (BCR-NLC) employing the Box-Behnken design (BBD). BCR-SLNs and BCR-NLCs were developed using the high-pressure homogenization method. The prepared nanoparticles were characterized for particle size (PS), polydispersity index (PDI), and entrapment efficiency (EE). In vitro drug release, cytotoxicity studies, in vivo plasma pharmacokinetic, and brain distribution studies evaluated the optimized lipid nanoparticles. The optimized BCR-SLN had a PS of 219.21 ± 1.3 nm, PDI of 0.22 ± 0.02, and EE of 72.2 ± 0.5. The PS, PDI, and EE of optimized BCR-NLC formulation were found to be 182.87 ± 2.2, 0.16 ± 0.004, and 83.57 ± 1.8, respectively. The in vitro release profile of BCR-SLN and BCR-NLC showed a biphasic pattern, immediate release, and then trailed due to the sustained release. Furthermore, a pharmacokinetic study indicated that both the optimized BCR-SLN and BCR-NLC formulations improve the plasma and brain bioavailability of the drug compared to the BCR solution. Based on the research findings, it can be concluded that the BCR-loaded lipid nanoparticles could be a promising carrier by enhancing the BBB penetration of the drug and helping in the improvement of the bioavailability and therapeutic efficacy of BCR in the management of PD.

17 January 2023 in Polymers
Verified
Journal Article
Open access
PDF file
YAYahya Alhamhoom
Yahya Alhamhoom
SHSandip M. Honmane
Sandip M. Honmane
UHUmme Hani
Umme Hani
RORiyaz Ali M Osmani
Riyaz Ali M Osmani
GKGeetha Kandasamy
Geetha Kandasamy
MCManoj S. Charde
Manoj S. Charde
Piroxicam is a Biopharmaceutical Classification System (BCS) Class II drug having poor aqueous solubility and a short half-life. The rationale behind the present research was to develop a Piroxicam nanosuspension to enhance the solubility and thereby the in vitro bioavailability of the drug. Piroxicam nanosuspension (PRX NS) was prepared by an anti-solvent precipitation technique and optimized using a full-factorial design. Herein, the nanosuspension was prepared using polymer polyvinylpyrrolidone (PVP) K30® and Poloxamer 188® as a stabilizer to improve the solubility and in vitro bioavailability of the drug. Nine formulations were prepared based on 32 full-factorial experimental designs to study the effect of the formulation variables such as concentration of poloxamer 188 (%) (X1) and stirring speed (rpm) (X2) as a process variable on the response of particle size (nm) and solubility (µg/mL). The prepared NS was characterized by phase solubility, Fourier-transform infrared (FT-IR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), transmission electron microscopy (TEM), particle size, zeta potential, entrapment efficiency, and percent drug release. DSC and XRPD analysis of freeze-dried NS formulation showed conversion of PRX into a less crystalline form. NS formulations showed a reduction in the size from 443 nm to 228 nm with −22.5 to −30.5 mV zeta potential and % drug entrapment of 89.76 ± 0.76. TEM analysis confirmed the size reduction at the nano level. The solubility was increased from 44 μg/mL to 87 μg/mL by altering the independent variables. The solubility of PRX NS in water was augmented by 14- to 15-fold (87.28 μg/mL) than pure PRX (6.6 μg/mL). The optimized formulation (NS9) at drug-to-stabilizer concentration exhibited a greater drug release of approximately 96.07% after 120 min as compared to the other NS formulations and pure PRX (36.78%). Thus, all these results revealed that the prepared NS formulations have improved the solubility and in vitro dissolution compared to the pure drug. Furthermore, an increase in the drug release was observed from the NS than that of the pure PRX. All these outcomes signified that the prepared PRX NS showed an increase in solubility and in vitro dissolution behavior; which subsequently would aid in attainment of enhanced bioavailability.
1

21 February 2023 in Therapeutic Delivery
Verified
Journal Article
Closed access
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
SPSharanya Vidyadhar Paramshetti
Sharanya Vidyadhar Paramshetti
PHPraveen Halagali
Praveen Halagali
VJVikas Jain
Vikas Jain
APAmit B Patil
Amit B Patil
PSPreethi Somanna
Preethi Somanna
Nanotechnological advancements over the past few years have led to the development of newer treatment strategies in brain cancer therapy which leads to the establishment of nano oncology. Nanostructures with high specificity, are best suitable to penetrate the blood–brain barrier (BBB). Their desired physicochemical properties, such as small sizes, shape, higher surface area to volume ratio, distinctive structural features, and the possibility to attach various substances on their surface transform them into potential transport carriers able to cross various cellular and tissue barriers, including the BBB. The review emphasizes nanotechnology-based treatment strategies for the exploration of brain tumors and highlights the current progress of different nanomaterials for the effective delivery of drugs for brain tumor therapy.
1

17 April 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
MKMadhuchandra Kenchegowda
Madhuchandra Kenchegowda
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
UHUmme Hani
Umme Hani
Adel Al FateaseAdel Al Fatease
Adel Al Fatease
FFfarhat fatima
farhat fatima
HKHeena Shijauddin Kazi
Heena Shijauddin Kazi